← Back to Clinical Trials
Recruiting NCT07604246

NCT07604246 Evaluating the Effect of Nicotine on Eye Movements and Related Behaviors in Electronic Cigarette Users, NICS-EYES Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07604246
Status Recruiting
Phase —
Sponsor Ohio State University Comprehensive Cancer Center
Condition Cigarette Smoking-Related Carcinoma
Study Type INTERVENTIONAL
Enrollment 25 participants
Start Date 2026-08-17
Primary Completion 2027-12-31

Eligibility & Interventions

Sex All sexes
Min Age 21 Years
Max Age 50 Years
Study Type INTERVENTIONAL
Interventions
AvoidanceBiospecimen CollectionCigarette Smoking

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 25 participants in total. It began in 2026-08-17 with a primary completion date of 2027-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This clinical trial evaluates the effect of nicotine on eye movements and related behaviors in people who use electronic (e)-cigarettes. Nicotine is an addictive, poisonous chemical found in tobacco. It can also be made in the laboratory. When it enters the body, nicotine causes an increased heart rate and the use of oxygen by the heart and a sense of well-being and relaxation. E-cigarettes are the most commonly used tobacco products in young adults in the United States. E-cigarettes deliver nicotine rapidly and the potential for addiction (abuse liability) is comparable to combustible cigarettes. The Food and Drug Administration uses a combination of testing including self-reported scales, withdrawal assessments and behavioral tasks to evaluate the abuse liability of a nicotine product. Research has shown that nicotine alters movement of the eye (oculomotor) and the amount of nicotine in the blood impacts the extent of oculomotor function impairment. Despite this evidence linking nicotine to oculomotor changes, it has not been studied as a reliable marker for abuse in e-cigarette users. Studying eye movements can provide information about how the brain responds to nicotine and may help researchers develop better, more objective ways to measure how addictive nicotine products in e-cigarette users.

Eligibility Criteria

Inclusion Criteria: * Age 21-50 years * Daily use of nicotine-containing electronic cigarettes for ≥ 6 months * Ability to abstain from nicotine for at least 12 hours prior to study visits * Fluent in English * Willingness to complete two in-person laboratory visits and all study procedures * Ability to provide informed consent Exclusion Criteria: * Use of combustible cigarettes or other tobacco/nicotine products on more than 5 of the past 30 days * Current enrollment in a nicotine cessation program or intent to quit in the next 30 days * Neurological conditions affecting eye movements (seizure disorder, movement disorders, head injury with loss of consciousness) * Normal or corrected-to-normal vision required; significant uncorrected visual impairment or ocular conditions affecting eye tracking * Cardiovascular conditions for which nicotine use is contraindicated, substance use disorder (other than nicotine), or current nicotine cessation treatment * Pregnancy or breastfeeding * Current medications affecting pupil size or eye movements (anticholinergics, stimulants, antipsychotics) * Any condition that, in the investigator's judgment, would interfere with safe participation * Age younger than 21 years or older than 50 years

Contact & Investigator

Central Contact

The Ohio State University Comprehensive Cancer Center

✉ OSUCCCClinicaltrials@osumc.edu

📞 800-293-5066

Principal Investigator

Patrick Tomko, PhD, CSCS

PRINCIPAL INVESTIGATOR

Ohio State University Comprehensive Cancer Center

Frequently Asked Questions

Who can join the NCT07604246 clinical trial?

This trial is open to participants of all sexes, aged 21 Years or older, up to 50 Years, studying Cigarette Smoking-Related Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07604246 currently recruiting?

Yes, NCT07604246 is actively recruiting participants. Contact the research team at OSUCCCClinicaltrials@osumc.edu for enrollment information.

Where is the NCT07604246 trial being conducted?

This trial is being conducted at Columbus, United States.

Who is sponsoring the NCT07604246 clinical trial?

NCT07604246 is sponsored by Ohio State University Comprehensive Cancer Center. The principal investigator is Patrick Tomko, PhD, CSCS at Ohio State University Comprehensive Cancer Center. The trial plans to enroll 25 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology